160 related articles for article (PubMed ID: 33672697)
1. Design and Synthesis of HCV-E2 Glycoprotein Epitope Mimics in Molecular Construction of Potential Synthetic Vaccines.
Meuleman TJ; Cowton VM; Patel AH; Liskamp RMJ
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672697
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
[TBL] [Abstract][Full Text] [Related]
3. Immobilization by Surface Conjugation of Cyclic Peptides for Effective Mimicry of the HCV-Envelope E2 Protein as a Strategy toward Synthetic Vaccines.
Meuleman TJ; Dunlop JI; Owsianka AM; van de Langemheen H; Patel AH; Liskamp RMJ
Bioconjug Chem; 2018 Apr; 29(4):1091-1101. PubMed ID: 29382188
[TBL] [Abstract][Full Text] [Related]
4. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding.
He L; Cheng Y; Kong L; Azadnia P; Giang E; Kim J; Wood MR; Wilson IA; Law M; Zhu J
Sci Rep; 2015 Aug; 5():12501. PubMed ID: 26238798
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
[TBL] [Abstract][Full Text] [Related]
6. Improving the aqueous solubility of HCV-E2 glycoprotein epitope mimics by cyclization using POLAR hinges.
Meuleman TJ; Cowton VM; Patel AH; Liskamp RMJ
J Pept Sci; 2020 Jan; 26(1):e3222. PubMed ID: 31984607
[TBL] [Abstract][Full Text] [Related]
7. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
8. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
[TBL] [Abstract][Full Text] [Related]
10. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them.
Quadeer AA; Louie RHY; McKay MR
Nat Commun; 2019 May; 10(1):2073. PubMed ID: 31061402
[TBL] [Abstract][Full Text] [Related]
11. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
13. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
[TBL] [Abstract][Full Text] [Related]
14. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
Ruwona TB; Giang E; Nieusma T; Law M
J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
[TBL] [Abstract][Full Text] [Related]
15. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
[TBL] [Abstract][Full Text] [Related]
16. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
[TBL] [Abstract][Full Text] [Related]
17. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
18. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
19. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development.
Ströh LJ; Krey T
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947858
[TBL] [Abstract][Full Text] [Related]
20. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
